FDA 483 - Mayne Pharma International PTY LTD - October 18, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Mayne Pharma International PTY LTD in Salisbury South, Australia, revealed deficiencies in the supervision of drug product manufacturing. Specifically, individuals responsible for overseeing production lacked the necessary experience, leading to improper gowning practices during a training session where exposed hair was observed in a manufacturing area. This lapse raises concerns about the assurance of drug product safety, identity, strength, quality, and purity.
ID · 5162ca21-55dc-4e9d-b7bb-ccfc77d8b37d